Role of monocarboxylate transporters in human cancers: state of the art - PubMed (original) (raw)
Review
Role of monocarboxylate transporters in human cancers: state of the art
Céline Pinheiro et al. J Bioenerg Biomembr. 2012 Feb.
Free article
Abstract
Monocarboxylate transporters (MCTs) belong to the SLC16 gene family, presently composed by 14 members. MCT1-MCT4 are proton symporters, which mediate the transmembrane transport of pyruvate, lactate and ketone bodies. The role of MCTs in cell homeostasis has been characterized in detail in normal tissues, however, their role in cancer is still far from understood. Most solid tumors are known to rely on glycolysis for energy production and this activity leads to production of important amounts of lactate, which are exported into the extracellular milieu, contributing to the acidic microenvironment. In this context, MCTs will play a dual role in the maintenance of the hyper-glycolytic acid-resistant phenotype of cancer, allowing the maintenance of the high glycolytic rates by performing lactate efflux, and pH regulation by the co-transport of protons. Thus, they constitute attractive targets for cancer therapy, which have been little explored. Here we review the literature on the role of MCTs in solid tumors in different locations, such as colon, central nervous system, breast, lung, gynecologic tract, prostate, stomach, however, there are many conflicting results and in most cases there are no functional studies showing the dependence of the tumors on MCT expression and activity. Additional studies on MCT expression in other tumor types, confirmation of the results already published as well as additional functional studies are needed to deeply understand the role of MCTs in cancer maintenance and aggressiveness.
Similar articles
- The SLC16 gene family - structure, role and regulation in health and disease.
Halestrap AP. Halestrap AP. Mol Aspects Med. 2013 Apr-Jun;34(2-3):337-49. doi: 10.1016/j.mam.2012.05.003. Mol Aspects Med. 2013. PMID: 23506875 Review. - Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?
Singh M, Afonso J, Sharma D, Gupta R, Kumar V, Rani R, Baltazar F, Kumar V. Singh M, et al. Semin Cancer Biol. 2023 May;90:1-14. doi: 10.1016/j.semcancer.2023.01.007. Epub 2023 Jan 24. Semin Cancer Biol. 2023. PMID: 36706846 Review. - Monocarboxylate transporters as targets and mediators in cancer therapy response.
Baltazar F, Pinheiro C, Morais-Santos F, Azevedo-Silva J, Queirós O, Preto A, Casal M. Baltazar F, et al. Histol Histopathol. 2014 Dec;29(12):1511-24. doi: 10.14670/HH-29.1511. Epub 2014 Jun 12. Histol Histopathol. 2014. PMID: 24921258 Review. - Monocarboxylate transporters in cancer.
Payen VL, Mina E, Van Hée VF, Porporato PE, Sonveaux P. Payen VL, et al. Mol Metab. 2020 Mar;33:48-66. doi: 10.1016/j.molmet.2019.07.006. Epub 2019 Jul 27. Mol Metab. 2020. PMID: 31395464 Free PMC article. Review. - Na(+)/H(+) antiporter (NHE1) and lactate/H(+) symporters (MCTs) in pH homeostasis and cancer metabolism.
Counillon L, Bouret Y, Marchiq I, Pouysségur J. Counillon L, et al. Biochim Biophys Acta. 2016 Oct;1863(10):2465-80. doi: 10.1016/j.bbamcr.2016.02.018. Epub 2016 Mar 2. Biochim Biophys Acta. 2016. PMID: 26944480 Review.
Cited by
- Role of monocarboxylate transporters in the diagnosis, progression, prognosis, and treatment of prostate cancer.
Rodriguez JER, Garcia-Perdomo HA. Rodriguez JER, et al. Turk J Urol. 2020 Nov;46(6):413-418. doi: 10.5152/tud.2020.20278. Epub 2020 Aug 20. Turk J Urol. 2020. PMID: 32833619 Free PMC article. Review. - Current Advances on Nanomaterials Interfering with Lactate Metabolism for Tumor Therapy.
Cheng Q, Shi XL, Li QL, Wang L, Wang Z. Cheng Q, et al. Adv Sci (Weinh). 2024 Jan;11(3):e2305662. doi: 10.1002/advs.202305662. Epub 2023 Nov 8. Adv Sci (Weinh). 2024. PMID: 37941489 Free PMC article. Review. - MR Molecular Imaging of Brain Cancer Metabolism Using Hyperpolarized 13C Magnetic Resonance Spectroscopy.
Najac C, Ronen SM. Najac C, et al. Top Magn Reson Imaging. 2016 Oct;25(5):187-196. doi: 10.1097/RMR.0000000000000104. Top Magn Reson Imaging. 2016. PMID: 27748711 Free PMC article. Review. - Mitochondrial-Targeting Anticancer Agent Conjugates and Nanocarrier Systems for Cancer Treatment.
Battogtokh G, Cho YY, Lee JY, Lee HS, Kang HC. Battogtokh G, et al. Front Pharmacol. 2018 Aug 17;9:922. doi: 10.3389/fphar.2018.00922. eCollection 2018. Front Pharmacol. 2018. PMID: 30174604 Free PMC article. Review. - NF-κB mediated regulation of tumor cell proliferation in hypoxic microenvironment.
Rastogi S, Aldosary S, Saeedan AS, Ansari MN, Singh M, Kaithwas G. Rastogi S, et al. Front Pharmacol. 2023 Feb 20;14:1108915. doi: 10.3389/fphar.2023.1108915. eCollection 2023. Front Pharmacol. 2023. PMID: 36891273 Free PMC article. Review.
References
- Neuroreport. 2001 Mar 26;12(4):761-5 - PubMed
- Br J Cancer. 2010 Sep 28;103(7):1008-18 - PubMed
- Histopathology. 2010 Jun;56(7):860-7 - PubMed
- Mol Pharmacol. 2006 Dec;70(6):2108-15 - PubMed
- Cancer Res. 2006 Jan 15;66(2):632-7 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources